Nuclear Medicine and Biology
Volume 37, Issue 8 , Pages 949-955 , November 2010

177Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer

  • Samira Rasaneh

      Affiliations

    • Department of Medical Physics, Faculty of Medical Sciences, Tarbiat Modares University, P.O. Box 14115-331, Tehran, Iran
    • ,
  • Hossein Rajabi

      Affiliations

    • Department of Medical Physics, Faculty of Medical Sciences, Tarbiat Modares University, P.O. Box 14115-331, Tehran, Iran
    • Corresponding Author InformationCorresponding author. Tel.: +98 21 82883894; fax: +98 21 88006544.
    • ,
  • Mohammad Hossein Babaei

      Affiliations

    • Department of Radioisotope, Nuclear Science and Technology Research Institute, 14115-331 Tehran, Iran
    • ,
  • Fariba Johari Daha

      Affiliations

    • Department of Radioisotope, Nuclear Science and Technology Research Institute, 14115-331 Tehran, Iran

Received 8 March 2010 ,Revised 30 May 2010 ,Accepted 1 July 2010.

References 

  1. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med. 2005;46:115–127
  2. Albanell J, Codony J, Rovira A, Mellado B, Gascon P. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Bio. 2003;532:253–268
  3. Natali PG, Nicotra MR, Bigotti A, Venturo I, Slamon DJ, Fendly BM, et al. Expressionof the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer. 1990;45(3):457–461
  4. Metro G, Mottolese M, Fabi A. HER-2-positive metastatic breast cancer: trastuzumab and beyond. Expert Opin Pharmacother. 2008;9(15):2583–2601
  5. Li G, Wang Y, Huang K, Zhang H, Peng W, Zhang C. The experimental study on the radioimmunotherapy of the nasopharyngeal carcinoma overexpressing HER2/neu in nude mice model with intratumoral injection of 188Re-herceptin. Nucl Med Biol. 2005;32(1):59–65
  6. Luoa TY, Tang IC, Wul YL, Hsua KL, Liub SW, Kungc HC. Evaluating the potential of 188Re-SOCTA-trastuzumab as a new radioimmunoagent for breast cancer treatment. Nucl Med Biol. 2009;36(1):81–88
  7. Costantini DL, Chan C, Cai Z, Vallis KA, Reilly RM. (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med. 2007;48(8):1357–1368
  8. Akabani G, Carlin S, Welsh P, Zalutsky MR. In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction. Nucl Med Biol. 2006;33(3):333–347
  9. Palm S, Enmon RM, Matei C, Kolbert KS, Xu S, Zanzonico PB, et al. Pharmacokinetics and biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI. J Nucl Med. 2003;44(7):1148–1155
  10. Davoli A, Hocevar BA, Brown TL. Progression and treatment of HER2-positive breast cancer. Cancer Chemother Pharmacol. 2010;65(4):611–623
  11. Seidman A, Hudis C, Pierri M, Shak S, Paton V, Ashby M. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20:1215–1221
  12. Fleck LM. The costs of caring: Who pays? Who profits? Who panders?. Hastings Cent Rep. 2006;36(3):13–17
  13. Rasaneh S, Rajabi H, Babaei MH, Johari-Daha F, Salouti M. Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer. Nucl Med Biol. 2009;36(4):363–369
  14. Rasaneh S, Rajabi H, Babaei MH, Johari-Daha F, Toxicity of trastuzumab labeled 177Lu on MCF7 and SKBr3 cell lines, Appl Radiat Isotopes, In Press, 12 May 2010.
  15. Koyama Y, Barrett T, Hama Y, Ravizzini G, Choyke PL, Kobayashi H. In vivo molecular imaging to diagnose and subtype tumors through receptor targeted optically labeled monoclonal antibodies. Neoplasia. 2007;9(12):1021–1029
  16. Mohsin H, Fitzsimmons J, Shelton T, Hoffman T, Cutler C, Lewis M. Preparation and biological evaluation of 111In, 177Lu and 90Y labeled DOTA analogues conjugated to B72.3. Nucl Med Biol. 2007;34:493–502
  17. Yordanov A, Hens M, Pegram C, Bigner D, Zalutsky M. Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands. Nucl Med Biol. 2007;34:173–183
  18. Brady ED, Chong HS, Milenic DE, Brechbiel MW. Development of a spectroscopic assay for bifunctional ligand-protein conjugates based on copper. J Nucl Med. 2004;31:795–802
  19. Lowry OH, Rosebrough NJ, Farr L, Randal RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265–269
  20. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PJ. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72:77–89
  21. Johnstone T, Thorpe R. In: Immunocytochemistry, immunohistochemistry and flow cytofluorimetry. Immunochemistry in practice. 3rd ed. Berlin: Blackwell Science; 1996;p. 313–380
  22. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003;2:131–137
  23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55–63
  24. Nayak D, Lahiri S. Application of radioisotopes in the field of nuclear medicine. J Radioanal Nucl Chem. 1999;242:423–432
  25. Brouwers AH, van Eerd JEM, Frielink C, Oosterwijk E, Oyen WJG, Corstens FHM, et al. Optimization of radioimmunotherapy of renal cell carcinoma: Labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. J Nucl Med. 2004;45:327–337
  26. Vallabhajosula S, Goldsmith S, Hamacher K, Kostakoglu L, Konishi S, Milowski M. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med. 2005;46:850–858

PII: S0969-8051(10)00319-7

doi: 10.1016/j.nucmedbio.2010.07.001

Nuclear Medicine and Biology
Volume 37, Issue 8 , Pages 949-955 , November 2010

Article Tools

* Image Usage & Resolution